

9/8/2006

PTO/SB/08a/b (07-06)

Approved for use through 09/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/989,687-Conf. #9708
				Filing Date	November 21, 2001
				First Named Inventor	Luisa Iruela Arispe
				Art Unit	1643
				Examiner Name	K. A. Canella
Sheet	1	of	1	Attorney Docket Number	PF453P3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number*Kind Code ² (if known)			
/KAC/	CQ	09/373,658	05-15-2003	Iruela-Arispe, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/KAC/	CR	WO 98/56804	12-17-1998	Human Genome Sciences, Inc.		
/KAC/	CS	AU 36226/00 (Based on WO 00/53774)	09-28-2000	Neurocrine Biosciences, Inc.		
/KAC/	CT	AU 766,787	08-09-1999	Human Genome Sciences, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAC/	CU	BREM, S. "Angiogenesis and Cancer Control: From Concept to Therapeutic Trial", <i>Cancer Control</i> , 1999, 6(5): 436-458.	
/KAC/	CV	BROOKS, P.C., et al., "Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3", 1996, <i>Cell</i> 85(5): 683-93.	
/KAC/	CW	DAS, R.C., "Proteins and antibodies make advances as therapeutic products", <i>American Biotechnology Laboratory</i> , 2000, 38-40.	
/KAC/	CX	KANG, I.C., et al., "A novel disintegrin salmosin inhibits tumor angiogenesis", <i>Cancer Res.</i> , 1999, 59(15): 3754-60.	
/KAC/	CY	MARKLAND, F.S., et al., "A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model", <i>Haemostasis</i> , 2001, 31(3-6): 183-91.	
/KAC/	CZ	PAVLOU, A.K., et al., "Recombinant protein therapeutics--success rates, market trends and values to 2010", <i>Nat Biotechnol</i> , 2004, 22(12): 1513-9.	
/KAC/	DA	SENGER, D.R., et al., "Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins", <i>Proc Natl Acad Sci USA</i> , 1997, 13612-7.	
/KAC/	DB	YBH, C.H., et al., "Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis", <i>Blood</i> , 1998, 92(9): 3268-76.	
/KAC/	DC	YBH, C.H., et al., "Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells", <i>Mol Pharmacol</i> , 2001, 59(5): 1333-42.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	05/14/2007
-----------------------	---------------------------	--------------------	------------